Schedule

Tony Robbins' Lifelong Mission to Feed Neighbors Reaches Milestone as Feeding America® Partnership Provides Historic 1 Billion Meals

Retrieved on: 
Wednesday, November 29, 2023

CHICAGO, Nov. 29, 2023 /PRNewswire/ -- Tony Robbins, #1 New York Times bestselling author, entrepreneur, philanthropist, and the world's #1 life and business strategist, together with Feeding America®, America's leading hunger relief organization, today proudly announce achieving their monumental 1 Billion Meals Challenge goal. This milestone, part of a unique 10-year challenge match campaign to fight hunger and food insecurity in the U.S., was reached significantly ahead of the 2025 target.

Key Points: 
  • In 2012, Mr. Robbins became an ambassador for Feeding America , a. nationwide network of 200 food banks and 60,000 food pantries and meal programs.
  • The 100 Million Meals Challenge grew to become a first-of-its-kind, 10-year 1 Billion Meals Challenge campaign.
  • With the 1 Billion meals milestone achieved, Mr. Robbins sets his sights even higher – aiming to end global food insecurity.
  • The 100 Billion Meals initiative provides resources to create sustainable solutions to end world hunger and food insecurity entirely.

iClick Interactive Asia Group Limited Enters into a Definitive Merger Agreement for Going-Private Transaction

Retrieved on: 
Friday, November 24, 2023

The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the "Special Committee"), unanimously approved the Merger Agreement and the Merger, and unanimously resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement and the Merger.

Key Points: 
  • The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the "Special Committee"), unanimously approved the Merger Agreement and the Merger, and unanimously resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement and the Merger.
  • The Special Committee negotiated the terms of the Merger Agreement with the assistance of its independent financial and legal advisors.
  • The Rollover Shareholders have agreed to vote all of the Shares beneficially owned by them in favor of the authorization and approval of the Merger Agreement and the Merger pursuant to the Support Agreement.
  • In connection with the Merger, the Company will prepare and mail a Schedule 13E-3 Transaction Statement (the "Schedule 13E-3").

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

Retrieved on: 
Monday, November 20, 2023

BALTIMORE, Nov. 20, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company, today announced a partnership with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder. Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments. This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.

Key Points: 
  • Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments.
  • This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.
  • Unlike Ketamine, which necessitates intravenous, intramuscular, or intranasal administration due to its limited oral bioavailability, in initial pre-clinical studies, Ketamir-2 appears to exhibit a more clinically desirable gastrointestinal absorption profile.
  • The combination of this exclusive licensing agreement and obtaining initial funding for development through the MIRALOGX line of credit propels MIRA into an exciting phase of innovation and development."

VNET Announces US$299 Million Strategic Investment from Shandong Hi-Speed Holdings Group Limited

Retrieved on: 
Thursday, November 16, 2023

BEIJING, Nov. 16, 2023 /PRNewswire/ -- VNET Group, Inc. (Nasdaq: VNET) ("VNET" or the "Company"), a leading carrier- and cloud-neutral internet data center services provider in China, today announced that Success Flow International Investment Limited ("Success Flow") and Choice Faith Group Holdings Limited ("Choice Faith") have entered into an investment agreement (the "Investment Agreement") with VNET to make an equity investment in an aggregate amount of US$299 million (the "Proposed Investment") in the Company.

Key Points: 
  • BEIJING, Nov. 16, 2023 /PRNewswire/ -- VNET Group, Inc. (Nasdaq: VNET) ("VNET" or the "Company"), a leading carrier- and cloud-neutral internet data center services provider in China, today announced that Success Flow International Investment Limited ("Success Flow") and Choice Faith Group Holdings Limited ("Choice Faith") have entered into an investment agreement (the "Investment Agreement") with VNET to make an equity investment in an aggregate amount of US$299 million (the "Proposed Investment") in the Company.
  • Both Success Flow and Choice Faith are beneficially owned by Shandong Hi-Speed Holdings Group Limited ("SDHG," 00412.HK), the shares of which are listed on the Main Board of The Hong Kong Stock Exchange.
  • The closing of the Proposed Investment is expected to occur around the end of 2023 or January 2024.
  • "Their investment will further strengthen our balance sheet and fuel innovation as we will cooperatively explore new opportunities in renewable energies with them going forward.

Societal CDMO Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023

ET

Key Points: 
  • ET
    SAN DIEGO and GAINESVILLE, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third quarter and nine months ended September 30, 2023.
  • “Given the achievements of the quarter combined with our leaner and highly focused operation, I wish to emphasize the optimism we have for the future of Societal CDMO.
  • Financial Results for the Three Months Ended September 30, 2023
    Revenues for the quarter ended September 30, 2023, were $23.6 million, compared to $21.6 million for the comparable 2022 period.
  • Financial Results for the Nine Months Ended September 30, 2023
    Revenue for the nine months ended September 30, 2023, was $66.9 million, compared to $65.9 million for 2022.

Arco to Hold Extraordinary General Meeting of Shareholders

Retrieved on: 
Tuesday, November 7, 2023

Shareholders of record at the close of business in the Cayman Islands on November 7, 2023 will be entitled to attend and vote at the EGM and any adjournment thereof.

Key Points: 
  • Shareholders of record at the close of business in the Cayman Islands on November 7, 2023 will be entitled to attend and vote at the EGM and any adjournment thereof.
  • INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE SCHEDULE 13E-3 AND OTHER MATERIALS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE MERGER AND RELATED MATTERS.
  • The Company and certain of its directors and executive officers may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from the shareholders with respect to the proposed Merger.
  • Information regarding the persons who may be considered “participants” in the solicitation of proxies is set forth in the Schedule 13E-3.

Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, November 7, 2023

Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.
  • ZURZUVAE is being developed and commercialized in collaboration with Biogen Inc. Sage also commercializes ZULRESSO® (brexanolone) CIV injection in the treatment of PPD.
  • Restructuring Expenses: Restructuring expenses were $33.6 million in the third quarter of 2023 due to the August 2023 corporate reorganization.
  • ET to review its third quarter 2023 financial results and discuss recent corporate updates.

Marathon Digital Holdings Announces Bitcoin Production and Mining Operation Updates for October 2023

Retrieved on: 
Friday, November 3, 2023

Fort Lauderdale, FL, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Marathon Digital Holdings, Inc. (NASDAQ:MARA) ("Marathon" or "Company"), a leader in supporting and securing the Bitcoin ecosystem, today published unaudited bitcoin (“BTC”) production and miner installation updates for October 2023.

Key Points: 
  • Reported bitcoin holdings exclude 571 BTC that have been pledged as collateral in a hedge transaction.
  • With both hash rate and bitcoin production increasing, Marathon opted to sell 961 BTC to cover its associated direct costs.
  • The company intends to sell a portion of its bitcoin holdings in future periods to support monthly operations, manage its treasury, and for general corporate purposes.
  • Future changes in the network-wide mining difficulty rate or Bitcoin hash rate may also materially affect the future performance of Marathon's production of bitcoin.

Prospect Capital Corporation Announces Launch of Cash Tender Offer For its 5.35% Series A Fixed Rate Cumulative Perpetual Preferred Stock

Retrieved on: 
Monday, October 30, 2023

As described in the Offer to Purchase, tendered Shares may be validly withdrawn from the Tender Offer at or prior to the Expiration Date.

Key Points: 
  • As described in the Offer to Purchase, tendered Shares may be validly withdrawn from the Tender Offer at or prior to the Expiration Date.
  • The Company may amend, extend or, subject to certain conditions and applicable law, terminate the Tender Offer at any time in its sole discretion.
  • King & Co., Inc. to serve as the Information and Tender Agent for the Shares in the Tender Offer.
  • None of the Company or the Information and Tender Agent are making any recommendation as to whether or not holders should tender their Shares in connection with the Tender Offer.

Public Inquiry Into Foreign Interference Gets to Work

Retrieved on: 
Thursday, November 2, 2023

OTTAWA, ON, Nov. 2, 2023 /CNW/ - The Public Inquiry into Foreign Interference in Federal Electoral Processes and Democratic Institutions has begun its work.

Key Points: 
  • OTTAWA, ON, Nov. 2, 2023 /CNW/ - The Public Inquiry into Foreign Interference in Federal Electoral Processes and Democratic Institutions has begun its work.
  • The Inquiry will hold public hearings in each phase of its work.
  • "The work to set up an independent Public Inquiry, particularly one that deals with national security issues, is complex," said Commissioner Hogue.
  • The Inquiry will also set up a process so that members of the public can submit information to the Inquiry and/or share their observations.